

Novonesis issues EUR 1.7 billion senior unsecured notes

On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026.

Investor News
March 13, 2026

The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%.

Novonesis has been rated A- (stable outlook) by Standard & Poor's (S&P).

The net proceeds from the transaction will be used to refinance existing debt and for general corporate purposes.

For further details about the EMTN Programme and this issuance, please visit our [website](#).

Contact information

Investor Relations

Tobias Bjorklund	+45 3077 8682	tobb@novonesis.com
Anders Enevoldsen	+45 5350 1453	adev@novonesis.com

Treasury

Frants Bisgaard Pedersen	+45 3077 0342	fbp@novonesis.com
--------------------------	---------------	-------------------

Media Relations

Jens Gamborg	+45 3077 7182	jgam@novonesis.com
--------------	---------------	--------------------

Novonesis is a global company leading the era of biosolutions.

By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.

Novozymes A/S, part of
Novonesis Group
Krogshøjvej 36
2880 Bagsvaerd
Denmark